EOS imaging acquires exclusive rights to scoliosis software
EOS imaging, a company specialising in 2D/3D orthopaedic medical imaging, has announced that it has acquired the rights to an exclusive, worldwide licence for a technology dedicated to the prognosis of adolescent scoliosis using 3D and 2D clinical parameters obtained from EOS® systems. A multi-centre clinical study has launched in eight centres equipped with EOS systems (in the USA, Canada, France, Japan, Singapore and Hong Kong) to measure the technology’s ability to predict the risk of young patients with mild scoliosis later developing a severe deformity.
The software’s algorithm, developed by Montreal-based surgeons and engineers, uses several clinical parameters available in patient reports from the sterEOS workstation. It establishes a predictive score, which could measure the risk of a patient at an early, mild stage of scoliosis developing a severe form of the pathology.
“This promising technology confirms the value of the 3D data naturally associated with EOS images in developing applications and services dedicated to orthopaedic care pathways,” said CEO Marie Meynadier. “Acquiring these exclusive rights is an integral part of our global strategy to offer doctors not only cutting-edge imaging technology, but also a full suite of software and services to help them in their therapeutic strategies and execution, to the greatest benefit to patients.”
Treating scoliosis, whether via surgery or using a brace, is invasive. The ability to predict the risk of scoliosis progressing can facilitate both the choice of therapy – surgery or a brace – and its acceptance by young patients. Although its efficacy has been proven, wearing a brace can be difficult to accept for adolescent patients. In this area, EOS imaging is also involved in programs targeting the improvement of brace design using 3D information of the spine, ribcage and patient body contours.
